ID | 1117 |
Name of the vaccine | Typherix |
Microbe | Bacteria |
Disease name | Typhoid |
Name of bacteria | Salmonella typhi |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | Over 2 years |
Description of the vaccine | Vi polysaccharide typhoid vaccine. |
Name of the manufacturer | GlaxoSmithKline Biologicals |
Name of the manufacturing country | Belgium |
Year of manufacture | 2001 |
Clinical Phase status | Approved |
Bacterial strain | Gram negative bacteria. |
Efficacy | NA |
Vaccine formulation | Solution for injection |
Dosage | Single dose of 0.5 mL.
Subjects who remain at risk should be revaccinated using a single dose every 3 years. |
Mechanism of action | Production of IgG antibodies and is T cell independent. |
Route of administration | Intramuscular |
Indications | Against typhoid fever for adults and children. |
Export | Marketing Authorisation Holder - GlaxoSmithKline (Thailand) Ltd. |
Approval | WHO and European Pharmacopoeia |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | Redness, pain, swelling, fever, headache, general aches, malaise, nausea and itching. |
Post vaccination | NA |
Dose type | Single dose |
Interspecies transfer | NA |
PubMed identifier | 24599532 |
Clinical trial number | NA |
Reference | https://www.fda.moph.go.th/sites/drug/Summary/1C_1_44_NG_Typherix.pdf |
Other name | NA |
Additional Links | NA
|